# Task 5 Validation Report: LLM Response Generation

## Overview

This validation tests the two-step LLM response generation process:
1. **Research Summarizer**: Summarizes enriched papers chronologically with no loss of information
2. **Response Generator**: Generates final answer based on summary + user question

**Validation Date:** 2026-02-08T22:41:13.223Z
**Test Cases:** 3
**Success Rate:** 3/3 (100.0%)
**Average Execution Time:** 14864ms

---

## Graph Flow

```
START → scopeClassifier → queryParser → vectorSearch → pubmedFetch → researchSummarizer → responseGenerator → END
```

**New Nodes:**
- `researchSummarizer`: Uses Gemini 2.0 Flash to create comprehensive chronological summaries
- `responseGenerator`: Uses Gemini 2.0 Flash to generate natural language responses

---

## Test Results

### Test Case 1: Medical query about diabetes treatments - should show chronological evolution

**Query:** "What are the latest treatments for diabetes?"

**Status:** ✅ Success

**Metrics:**
- Execution Time: 14505ms
- Medical Query: true
- Parsed Query: "diabetes treatment management therapeutic interventions"
- Retrieved Documents: 10
- Research Summary Length: 4468 characters
- Final Response Length: 2164 characters

**Retrieved Papers:**

1. **A Narrative Review of Diabetes Intervention Studies to Explore Diabetes Care Opportunities for Pharmacists**
   - PMID: 27247949
   - Date: 2016
   - Score: 0.7343
   - Abstract Preview: Background. We conducted a review of current diabetes intervention studies in type 2 diabetes and identified opportunities for pharmacists to deliver quality diabetes care. Methods. A search on random...

2. **Editorial: Achieving Effective Management and Treatment of Diabetes Mellitus in Future Primary Care**
   - PMID: 35370957
   - Date: 2022
   - Score: 0.7285
   - Abstract Preview: ...

3. **Editorial: Psychological Interventions to Improve Diabetes Self-Management**
   - PMID: 36992746
   - Date: 2022
   - Score: 0.7168
   - Abstract Preview: ...

4. **Assessing the Effectiveness of Digital Health Behavior Strategies on Type 2 Diabetes Management: Systematic Review and Network Meta-Analysis**
   - PMID: 39951722
   - Date: 2025 Feb 14
   - Score: 0.7146
   - Abstract Preview: Various mobile technologies and digital health interventions (DHIs) have been developed for type 2 diabetes mellitus (T2DM) management. Strategies are crucial for ensuring the effectiveness of DHIs. H...

5. **Current Advances in the Management of Diabetes Mellitus**
   - PMID: 36289697
   - Date: 2022 Sep 29
   - Score: 0.7135
   - Abstract Preview: Diabetes mellitus (DM) underscores a rising epidemic orchestrating critical socio-economic burden on countries globally. Different treatment options for the management of DM are evolving rapidly becau...

**Research Summary (Preview):**

```
Here's a chronological summary of the provided diabetes research papers:

**Date Unknown:**

*   **Paper 9: Dietary and Behavioral Interventions for Diabetes: Current Evidence, Challenges, and Opportunities (PMID: 0)**
    *   No abstract available.

**2016:**

*   **Paper 1: A Narrative Review of Diabetes Intervention Studies to Explore Diabetes Care Opportunities for Pharmacists (PMID: 27247949)**
    *   Identified that diabetes management interventions often lack a standardized, comprehensiv...
```

**Final Response:**

```
The latest treatments for diabetes encompass a range of approaches, with recent research emphasizing technological and pharmacological advancements alongside established lifestyle interventions. Here's a summary of current options:

*   **Digital Health Interventions (DHIs):** A 2025 systematic review and meta-analysis (PMID: 39951722) found that DHIs, particularly those incorporating communication, engagement, guidance, and management strategies, are effective in reducing HbA1c levels, fasting blood glucose (FBG) levels, BMI, and weight in type 2 diabetes management.
*   **Digital Diabetes Management Technologies (DDMTs):** Another 2025 systematic review (PMID: 40525059) highlights the effectiveness of DDMTs like mobile apps, continuous glucose monitoring (CGM), telemedicine, smart insulin pens, and artificial intelligence (AI) in improving blood glucose levels compared to standard self-care. Personalized coaching and real-time feedback are crucial components.
*   **Pharmacological Treatments:** A 2023 review (PMID: 38283440) emphasizes the importance of GLP-1 receptor agonists and SGLT2 inhibitors. GLP-1 receptor agonists stimulate insulin production and offer cardiovascular benefits, while SGLT2 inhibitors increase glucose excretion and provide cardiovascular and renal protection.
*   **Lifestyle Management:** Research consistently emphasizes the importance of lifestyle management, alongside pharmacological approaches, for effective and safe diabetes treatment (PMID: 36289697).
*   **Diabetes Self-Management Education and Support (D-SMES):** A 2025 meta-analysis focusing on the WHO Africa Region (PMID: 40529214) indicates that D-SMES interventions are moderately effective in controlling blood glucose levels in type 2 diabetes patients.

It's important to note that a 2016 review (PMID: 27247949) pointed out the lack of a standardized, comprehensive approach in many diabetes management interventions, highlighting the need to address all seven factors outlined in diabetes guidelines (glycemic control, cholesterol, blood pressure, medication, lifestyle, education, and cardiovascular risk factors) for long-term care.
</response>
```

---

### Test Case 2: Medical query about COVID-19 - should cite recent research with dates

**Query:** "How does COVID-19 affect the cardiovascular system?"

**Status:** ✅ Success

**Metrics:**
- Execution Time: 15684ms
- Medical Query: true
- Parsed Query: "COVID-19 cardiovascular effects heart complications"
- Retrieved Documents: 10
- Research Summary Length: 4875 characters
- Final Response Length: 2637 characters

**Retrieved Papers:**

1. **Cardiovascular Complications of COVID-19 Disease: A Narrative Review**
   - PMID: 40863226
   - Date: 2025 Aug 08
   - Score: 0.8313
   - Abstract Preview: The coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has had a profound impact on global health, extending beyond pulmonary complications. Cardiovascular involvement in COVID-19 is multifact...

2. **COVID-19 and Cardiovascular Complications: A Follow-Up Study from Tertiary Center**
   - PMID: 41157565
   - Date: 2025 Sep 24
   - Score: 0.8102
   - Abstract Preview: (1) Background: In addition to its fatal outcomes, COVID-19 is associated with a spectrum of non-fatal complications that significantly influence clinical trajectories and quality of life. Cardiovascu...

3. **Cardiac Complications and COVID-19: A Review of Life-threatening Co-morbidities**
   - PMID: 38415433
   - Date: 2024
   - Score: 0.7994
   - Abstract Preview: The novel 2019 coronavirus disease (COVID-19) was first reported in the last days of December 2019 in Wuhan, China. The presence of certain co-morbidities, including cardiovascular diseases (CVDs), ar...

4. **Post-coronavirus Disease 2019 (COVID-19) Cardiovascular Manifestations: A Systematic Review of Long-Term Risks and Outcomes**
   - PMID: 40438846
   - Date: 2025 Apr
   - Score: 0.7953
   - Abstract Preview: Emerging evidence suggests that coronavirus disease 2019 (COVID-19) survivors face increased risks of cardiovascular complications, but the long-term risks, underlying mechanisms, and clinical implica...

5. **Pathophysiology of Cardiovascular Complications in COVID-19**
   - PMID: 33162899
   - Date: 2020
   - Score: 0.7906
   - Abstract Preview: Numerous recent studies have shown that patients with underlying cardiovascular disease (CVD) are at increased risk of more severe clinical course as well as mortality of COVID-19. Also, the available...

**Research Summary (Preview):**

```
Here's a chronological summary of the provided research papers on cardiovascular complications of COVID-19:

*   **2020:**
    *   **Paper 5 (PMID: 33162899):** This review highlights that patients with pre-existing cardiovascular disease (CVD) are at higher risk for severe COVID-19 and mortality. It also notes the emergence of *de novo* cardiovascular complications, especially in older individuals with cardiometabolic conditions. The paper discusses potential pathophysiological mechanisms, incl...
```

**Final Response:**

```
COVID-19 can affect the cardiovascular system in several ways, both during the acute infection phase and in the longer term. Here's a breakdown of the effects, according to the research:

*   **Increased Risk for Those with Pre-existing CVD:** Individuals with pre-existing cardiovascular diseases (CVD) are at a higher risk of experiencing severe COVID-19 and facing increased mortality (PMID: 33162899, 2020; PMID: 38415433, 2024; PMID: 40428732, 2025).

*   **Acute Cardiovascular Complications:** During the active phase of COVID-19, several cardiac complications can arise (PMID: 34046852, 2021; PMID: 37168413, 2023; PMID: 40863226, 2025):
    *   Myocardial injury and myocarditis (inflammation of the heart muscle)
    *   Arrhythmias (irregular heartbeats), particularly atrial fibrillation
    *   Acute coronary syndromes
    *   Heart failure
    *   Takotsubo cardiomyopathy (stress-induced heart weakening)
    *   Myopericarditis (inflammation of the heart muscle and surrounding sac)
    *   Cardiac arrest

*   **Mechanisms of Cardiovascular Damage:** Several mechanisms contribute to cardiovascular damage (PMID: 33162899, 2020; PMID: 35746609, 2022; PMID: 37168413, 2023; PMID: 40428732, 2025):
    *   Direct viral entry into heart cells (cardiomyocytes)
    *   Systemic hyperinflammation and cytokine release syndrome
    *   Hypercoagulability (increased blood clotting)
    *   Endothelial injury (damage to the lining of blood vessels)
    *   Hypoxemia (low blood oxygen)
    *   RAAS (renin-angiotensin-aldosterone system) dysregulation
    *   Plaque destabilization

*   **Post-COVID-19 Cardiovascular Issues:** Even after the acute infection resolves, cardiovascular problems can persist (PMID: 40438846, 2025; PMID: 40428732, 2025; PMID: 40863226, 2025):
    *   Endothelial dysfunction
    *   Myocardial inflammation
    *   Autonomic dysregulation
    *   Persistent arrhythmias
    *   Subclinical myocardial injury

*   **Prognostic Factors:** Certain factors are associated with poorer outcomes (PMID: 34901278, 2021; PMID: 40438846, 2025):
    *   Older age (over 60)
    *   Diabetes mellitus
    *   Hyperlipidemia
    *   Hospitalization
    *   Pre-existing CVD
    *   Metabolic syndrome
    *   Right ventricular dysfunction

*   **Pediatric Considerations:** Pediatric inflammatory multisystem syndrome is a major cause of cardiovascular complications in children (PMID: 33162899, 2020).

It's important to note that while ST-T fragment changes were a common arrhythmia in one study, there was no significant association between specific arrhythmia types and patient outcomes (PMID: 34901278,
```

---

### Test Case 3: Medical query about medication - should summarize findings from multiple papers

**Query:** "What are the side effects of statins?"

**Status:** ✅ Success

**Metrics:**
- Execution Time: 14402ms
- Medical Query: true
- Parsed Query: "statins adverse effects side effects complications"
- Retrieved Documents: 10
- Research Summary Length: 4559 characters
- Final Response Length: 2057 characters

**Retrieved Papers:**

1. **Hepatotoxicity of statins: a real-world study based on the US Food and Drug Administration Adverse Event Reporting System database**
   - PMID: 39840096
   - Date: 2024
   - Score: 0.7871
   - Abstract Preview: Statins, as an important class of lipid-lowering drugs, play a key role in the prevention and treatment of cardiovascular diseases. However, with their widespread use in clinical practice, some advers...

2. **Comparative Analysis of Adverse Event Profiles Among Seven Statins for Hypercholesterolemia Management Using the United States FDA Adverse Event Reporting System**
   - PMID: 40291284
   - Date: 2025 Mar
   - Score: 0.7812
   - Abstract Preview: Background Statins are fundamental in hypercholesterolemia management, with seven primary drugs available: atorvastatin, simvastatin, rosuvastatin, pravastatin, lovastatin, fluvastatin, and pitavastat...

3. **Potential Benefits and Risks Associated with the Use of Statins**
   - PMID: 38399268
   - Date: 2024 Feb 01
   - Score: 0.7791
   - Abstract Preview: HMG-CoA reductase inhibitors, commonly known as statins, are the primary treatment choice for cardiovascular diseases, which stand as the leading global cause of mortality. Statins also offer various ...

4. **A Meta-Analysis of the Incidence of Adverse Reactions of Statins in Various Diseases**
   - PMID: 40529509
   - Date: 2025
   - Score: 0.7761
   - Abstract Preview: Introduction: In clinical practice, patients often avoid or cease statin use due to adverse reactions or noncompliance. To elucidate statin adverse reactions, their variability across diseases, and th...

5. **A Survey of the FDA's AERS Database Regarding Muscle and Tendon Adverse Events Linked to the Statin Drug Class**
   - PMID: 22936996
   - Date: 2012
   - Score: 0.7635
   - Abstract Preview: Cholesterol management drugs known as statins are widely used and often well tolerated; however, a variety of muscle-related side effects can arise. These adverse events (AEs) can have serious impact,...

**Research Summary (Preview):**

```
Here's a chronological summary of the provided research papers on statins, focusing on key findings and the evolution of understanding:

*   **2012 (PMID: 22936996):** A study of the FDA Adverse Event Reporting System (AERS) database from 2005-2011 found that muscle-related adverse events (AEs) varied among statins. Rosuvastatin had the highest relative risk, followed by atorvastatin and simvastatin, with pravastatin and lovastatin having the lowest. The risk appeared to correlate with LDL-lower...
```

**Final Response:**

```
Statins can have a range of side effects, as indicated by several research studies. Here's a breakdown:

*   **Muscle-related issues:** These are a common concern. A 2012 study (PMID: 22936996) using the FDA AERS database (2005-2011) found that the risk of muscle-related adverse events varied among different statins. Rosuvastatin, atorvastatin, and simvastatin had higher relative risks, while pravastatin and lovastatin had lower risks. Potency of the statin seemed to correlate with this risk. A 2022 review (PMID: 35955495) also highlighted neuromuscular adverse effects like muscle cramps, myalgia, weakness, myopathy, and rhabdomyolysis as significant issues. A 2025 meta-analysis (PMID: 40529509) found that myalgia risk can vary depending on the patient population and statin dosage.

*   **Psychiatric adverse reactions:** Analysis of the EudraVigilance database (2004-2021) in 2022 (PMID: 36558987) revealed that atorvastatin, simvastatin, and rosuvastatin were most frequently reported for psychiatric adverse drug reactions (ADRs). Insomnia was the most common ADR, and the study suggested a potential link between statins and psychiatric side effects like nightmares and depression.

*   **Liver toxicity:** A 2024 study (PMID: 39840096) analyzing the FDA AERS database (2004-2024) identified 14,511 cases of hepatic disorders associated with statins. Atorvastatin, simvastatin, and rosuvastatin were reported at higher rates. The study found signals for autoimmune hepatitis and drug-induced liver injury.

*   **Other potential side effects:** A 2024 review (PMID: 38399268) mentions statin-associated symptoms (SAS) such as type 2 diabetes, kidney diseases, cataracts, hemorrhagic strokes, and psychiatric complications.

*   **Individual Variation:** A 2025 meta-analysis (PMID: 40529509) of 41 clinical trials found that adverse reactions to statins can differ across various diseases and patient populations.

It's important to note that the specific adverse event profiles can vary among different statins (PMID: 40291284 - 2025 study).
```

---

## Conclusion

✅ **All test cases passed successfully!**

The LLM response generation is working as expected:
- Research papers are being summarized chronologically with temporal context
- Final responses are natural, comprehensive, and cite sources appropriately
- Publication dates are considered in the analysis
- Average execution time is reasonable at 14864ms

---

## Raw Output

<details>
<summary>Click to expand full JSON output</summary>

```json
[
  {
    "testCase": 1,
    "query": "What are the latest treatments for diabetes?",
    "description": "Medical query about diabetes treatments - should show chronological evolution",
    "success": true,
    "executionTime": 14505,
    "isMedical": true,
    "parsedQuery": "diabetes treatment management therapeutic interventions",
    "retrievedDocsCount": 10,
    "researchSummaryLength": 4468,
    "researchSummaryPreview": "Here's a chronological summary of the provided diabetes research papers:\n\n**Date Unknown:**\n\n*   **Paper 9: Dietary and Behavioral Interventions for Diabetes: Current Evidence, Challenges, and Opportunities (PMID: 0)**\n    *   No abstract available.\n\n**2016:**\n\n*   **Paper 1: A Narrative Review of Diabetes Intervention Studies to Explore Diabetes Care Opportunities for Pharmacists (PMID: 27247949)**\n    *   Identified that diabetes management interventions often lack a standardized, comprehensiv",
    "researchSummaryFull": "Here's a chronological summary of the provided diabetes research papers:\n\n**Date Unknown:**\n\n*   **Paper 9: Dietary and Behavioral Interventions for Diabetes: Current Evidence, Challenges, and Opportunities (PMID: 0)**\n    *   No abstract available.\n\n**2016:**\n\n*   **Paper 1: A Narrative Review of Diabetes Intervention Studies to Explore Diabetes Care Opportunities for Pharmacists (PMID: 27247949)**\n    *   Identified that diabetes management interventions often lack a standardized, comprehensive approach encompassing all seven factors outlined in diabetes guidelines (glycemic control, cholesterol, blood pressure, medication, lifestyle, education, and cardiovascular risk factors).\n    *   Highlighted the need for intervention strategies that address all seven evidence-based factors to achieve long-term continuity of care.\n    *   The varied HbA1C reduction suggests a lack of standardised and consistent approach to diabetes care.\n\n**2022:**\n\n*   **Paper 2: Editorial: Achieving Effective Management and Treatment of Diabetes Mellitus in Future Primary Care (PMID: 35370957)**\n    *   No abstract available.\n\n*   **Paper 3: Editorial: Psychological Interventions to Improve Diabetes Self-Management (PMID: 36992746)**\n    *   No abstract available.\n\n*   **Paper 5: Current Advances in the Management of Diabetes Mellitus (PMID: 36289697)**\n    *   Highlights progress in diabetes management using treatments like nanotechnology, gene therapy, stem cells, medical nutrition therapy, and lifestyle modification.\n    *   Identifies challenges including optimization for glycemic, lipid, and blood pressure control, patient compliance, safety, ethical issues, and effective delivery systems.\n    *   Concludes that lifestyle management alongside pharmacological approaches is critical for effective and safe treatment.\n\n**2023:**\n\n*   **Paper 6: Novel Therapies in Diabetes: A Comprehensive Narrative Review of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Beyond (PMID: 38283440)**\n    *   Reviews the significance of GLP-1 receptor agonists and SGLT2 inhibitors in modern diabetes management.\n    *   GLP-1 receptor agonists replicate glucagon-like peptide-1, leading to glucose-dependent insulin production and cardiovascular benefits.\n    *   SGLT2 inhibitors act on renal glucose reabsorption, increasing glucose excretion and providing cardiovascular and renal protection.\n\n**2025:**\n\n*   **Paper 4: Assessing the Effectiveness of Digital Health Behavior Strategies on Type 2 Diabetes Management: Systematic Review and Network Meta-Analysis (PMID: 39951722)**\n    *   Systematic review and network meta-analysis identifying and categorizing strategies used in Digital Health Interventions (DHIs) for T2DM management.\n    *   Identified 63 strategies categorized into 19 themes, with \"guide, monitor, management, and engagement\" being the most common.\n    *   Specific strategy combinations (communication, engagement, guide, management) were most effective in reducing HbA1c levels, FBG levels, BMI, and weight.\n    *   Encourages healthcare professionals to apply these promising strategy combinations in DHIs during clinical care.\n\n*   **Paper 7: Digital Diabetes Management Technologies for Type 2 Diabetes: A Systematic Review of Home-Based Care Interventions (PMID: 40525059)**\n    *   Systematic review evaluating the effectiveness of digital diabetes management technologies (DDMTs) in optimizing blood glucose levels.\n    *   DDMTs (mobile apps, CGM, telemedicine, smart insulin pens, AI) significantly improve HbA1c, fasting blood glucose, and postprandial glucose compared to standard self-care.\n    *   Highlights the importance of personalized coaching and real-time feedback.\n    *   Identifies challenges such as digital health literacy, cost barriers, and long-term adherence.\n\n*   **Paper 8: Effectiveness of diabetes self-management education and support interventions on glycemic levels among people living with type 2 diabetes in the WHO African Region: a Systematic Review and meta-analysis (PMID: 40529214)**\n    *   Meta-analysis evaluating the effectiveness of diabetes self-management education and support (D-SMES) interventions in the WHO Africa Region.\n    *   D-SMES interventions are moderately effective in controlling blood glucose levels in T2DM patients.\n\n*   **Paper 10: The development of a CBT-informed approach to supporting type 2 diabetes self-management (PMID: 39981409)**\n    *   Describes the development of CBT",
    "finalResponseLength": 2164,
    "finalResponse": "The latest treatments for diabetes encompass a range of approaches, with recent research emphasizing technological and pharmacological advancements alongside established lifestyle interventions. Here's a summary of current options:\n\n*   **Digital Health Interventions (DHIs):** A 2025 systematic review and meta-analysis (PMID: 39951722) found that DHIs, particularly those incorporating communication, engagement, guidance, and management strategies, are effective in reducing HbA1c levels, fasting blood glucose (FBG) levels, BMI, and weight in type 2 diabetes management.\n*   **Digital Diabetes Management Technologies (DDMTs):** Another 2025 systematic review (PMID: 40525059) highlights the effectiveness of DDMTs like mobile apps, continuous glucose monitoring (CGM), telemedicine, smart insulin pens, and artificial intelligence (AI) in improving blood glucose levels compared to standard self-care. Personalized coaching and real-time feedback are crucial components.\n*   **Pharmacological Treatments:** A 2023 review (PMID: 38283440) emphasizes the importance of GLP-1 receptor agonists and SGLT2 inhibitors. GLP-1 receptor agonists stimulate insulin production and offer cardiovascular benefits, while SGLT2 inhibitors increase glucose excretion and provide cardiovascular and renal protection.\n*   **Lifestyle Management:** Research consistently emphasizes the importance of lifestyle management, alongside pharmacological approaches, for effective and safe diabetes treatment (PMID: 36289697).\n*   **Diabetes Self-Management Education and Support (D-SMES):** A 2025 meta-analysis focusing on the WHO Africa Region (PMID: 40529214) indicates that D-SMES interventions are moderately effective in controlling blood glucose levels in type 2 diabetes patients.\n\nIt's important to note that a 2016 review (PMID: 27247949) pointed out the lack of a standardized, comprehensive approach in many diabetes management interventions, highlighting the need to address all seven factors outlined in diabetes guidelines (glycemic control, cholesterol, blood pressure, medication, lifestyle, education, and cardiovascular risk factors) for long-term care.\n</response>",
    "retrievedDocs": [
      {
        "title": "A Narrative Review of Diabetes Intervention Studies to Explore Diabetes Care Opportunities for Pharmacists",
        "pmid": "27247949",
        "pubmed_date": "2016",
        "pubmed_abstract": "Background. We conducted a review of current diabetes intervention studies in type 2 diabetes and identified opportunities for pharmacists to deliver quality diabetes care. Methods. A search on random...",
        "score": 0.734333932
      },
      {
        "title": "Editorial: Achieving Effective Management and Treatment of Diabetes Mellitus in Future Primary Care",
        "pmid": "35370957",
        "pubmed_date": "2022",
        "pubmed_abstract": "...",
        "score": 0.728537321
      },
      {
        "title": "Editorial: Psychological Interventions to Improve Diabetes Self-Management",
        "pmid": "36992746",
        "pubmed_date": "2022",
        "pubmed_abstract": "...",
        "score": 0.716762
      },
      {
        "title": "Assessing the Effectiveness of Digital Health Behavior Strategies on Type 2 Diabetes Management: Systematic Review and Network Meta-Analysis",
        "pmid": "39951722",
        "pubmed_date": "2025 Feb 14",
        "pubmed_abstract": "Various mobile technologies and digital health interventions (DHIs) have been developed for type 2 diabetes mellitus (T2DM) management. Strategies are crucial for ensuring the effectiveness of DHIs. H...",
        "score": 0.714629173
      },
      {
        "title": "Current Advances in the Management of Diabetes Mellitus",
        "pmid": "36289697",
        "pubmed_date": "2022 Sep 29",
        "pubmed_abstract": "Diabetes mellitus (DM) underscores a rising epidemic orchestrating critical socio-economic burden on countries globally. Different treatment options for the management of DM are evolving rapidly becau...",
        "score": 0.713454187
      },
      {
        "title": "Novel Therapies in Diabetes: A Comprehensive Narrative Review of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Beyond",
        "pmid": "38283440",
        "pubmed_date": "2023 Dec",
        "pubmed_abstract": "Diabetes mellitus, a widespread metabolic illness with increasing global occurrence, continues to have a significant impact on public health. Diabetes is a condition marked by long-term high blood sug...",
        "score": 0.709657431
      },
      {
        "title": "Digital Diabetes Management Technologies for Type 2 Diabetes: A Systematic Review of Home-Based Care Interventions",
        "pmid": "40525059",
        "pubmed_date": "2025 May",
        "pubmed_abstract": "Digital diabetes management technologies (DDMTs) have emerged as promising tools for improving glycemic control in patients with type 2 diabetes mellitus (T2DM) receiving home-based care. This systema...",
        "score": 0.706044912
      },
      {
        "title": "Effectiveness of diabetes self-management education and support interventions on glycemic levels among people living with type 2 diabetes in the WHO African Region: a Systematic Review and meta-analysis",
        "pmid": "40529214",
        "pubmed_date": "2025",
        "pubmed_abstract": "For successful glycemic control, diabetes control requires a comprehensive management plan in which patients are educated and supported to make informed decisions about diet, exercise, weight control,...",
        "score": 0.705900848
      },
      {
        "title": "Dietary and Behavioral Interventions for Diabetes: Current Evidence, Challenges, and Opportunities",
        "pmid": "0",
        "pubmed_date": "Unknown",
        "pubmed_abstract": "undefined...",
        "score": 0.705515683
      },
      {
        "title": "The development of a CBT-informed approach to supporting type 2 diabetes self-management",
        "pmid": "39981409",
        "pubmed_date": "2025",
        "pubmed_abstract": "The self-management of adults with type 2 diabetes proves to be a continuous challenge. Within the South African context, socio-economic disparities, unequal access to healthcare and varying healthcar...",
        "score": 0.701012671
      }
    ]
  },
  {
    "testCase": 2,
    "query": "How does COVID-19 affect the cardiovascular system?",
    "description": "Medical query about COVID-19 - should cite recent research with dates",
    "success": true,
    "executionTime": 15684,
    "isMedical": true,
    "parsedQuery": "COVID-19 cardiovascular effects heart complications",
    "retrievedDocsCount": 10,
    "researchSummaryLength": 4875,
    "researchSummaryPreview": "Here's a chronological summary of the provided research papers on cardiovascular complications of COVID-19:\n\n*   **2020:**\n    *   **Paper 5 (PMID: 33162899):** This review highlights that patients with pre-existing cardiovascular disease (CVD) are at higher risk for severe COVID-19 and mortality. It also notes the emergence of *de novo* cardiovascular complications, especially in older individuals with cardiometabolic conditions. The paper discusses potential pathophysiological mechanisms, incl",
    "researchSummaryFull": "Here's a chronological summary of the provided research papers on cardiovascular complications of COVID-19:\n\n*   **2020:**\n    *   **Paper 5 (PMID: 33162899):** This review highlights that patients with pre-existing cardiovascular disease (CVD) are at higher risk for severe COVID-19 and mortality. It also notes the emergence of *de novo* cardiovascular complications, especially in older individuals with cardiometabolic conditions. The paper discusses potential pathophysiological mechanisms, including cytokine release syndrome, RAAS dysregulation, plaque destabilization, and coagulation disorders. Pediatric inflammatory multisystem syndrome is identified as a major cause of cardiovascular complications in children. The authors emphasize the need for clear clinical and follow-up protocols.\n\n*   **2021:**\n    *   **Paper 10 (PMID: 34901278):** This prospective study of 137 hospitalized COVID-19 patients assessed the frequency of cardiovascular complications and their association with prognosis. While ST-T fragment changes were the most common arrhythmia, the study found no significant association between specific arrhythmia types and patient outcomes. However, age over 60, diabetes mellitus, and hyperlipidemia were significantly associated with poorer prognosis.\n    *   **Paper 9 (PMID: 34046852):** This review describes increased rates of cardiac complications (CC) in the active phase of COVID-19, including myocarditis/myocardial injury, arrhythmias, and heart failure. It discusses mechanisms such as direct viral entry into cardiomyocytes, systemic hyperinflammation, hypercoagulability, endothelial injury, and hypoxemia. The review highlights the significant impact of CC on COVID-19 prognosis, with mortality rates exceeding 50% in patients with myocardial damage.\n*   **2022:**\n    *   **Paper 7 (PMID: 35746609):** This review focuses on the extrapulmonary manifestations of COVID-19, specifically cardiovascular involvement. It acknowledges that cardiovascular cells are targets of SARS-CoV-2 infection and associated disease pathogenesis. The paper outlines proposed disease mechanisms, including direct viral infection, effects of non-infectious viral particles, and inflammatory mediators.\n\n*   **2023:**\n    *   **Paper 6 (PMID: 37168413):** This systematic review of 97 articles focuses on acute cardiovascular complications of COVID-19. Cytokine-induced inflammation and direct cardiac damage are identified as significant mechanisms. Patients with underlying cardiovascular conditions (hypertension, diabetes) are at increased risk. Acute myocardial infarction and arrhythmias are common complications, along with myocarditis, Takotsubo syndrome, thromboembolic events, and pericardial complications.\n\n*   **2024:**\n    *   **Paper 3 (PMID: 38415433):** This review highlights that pre-existing cardiovascular diseases (CVDs) lead to worse outcomes in COVID-19 patients. It discusses the association of heart failure (HF) with increased hemodynamic load, ischemia-related dysfunction, ventricular remodeling, excessive neurohumoral stimulation, abnormal myocyte calcium cycling, and extracellular matrix proliferation. The review also mentions that inflammatory reactions lead to myocardial infarction (MI), and the virus can induce heart arrhythmia through cardiac complications, hypoxia, decreased heart hemodynamics, and remarkable inflammatory markers.\n\n*   **2025:**\n    *   **Paper 4 (PMID: 40438846):** This systematic review synthesizes evidence on post-COVID-19 cardiovascular manifestations. It identifies mechanisms such as endothelial dysfunction, myocardial inflammation, and autonomic dysregulation. Persistent arrhythmias and subclinical myocardial injury are common. Worse outcomes are associated with hospitalization, pre-existing CVD, and metabolic syndrome. The authors advocate for cardiovascular surveillance and risk-stratified care.\n    *   **Paper 8 (PMID: 40428732):** This narrative review explores the burden of SARS-CoV-2 infection on cardiovascular health, focusing on the post-COVID-19 condition. It investigates pathophysiological mechanisms, including direct viral invasion, immune-mediated injury, cytokine storm, endothelial dysfunction, and mitochondrial injury. The review emphasizes the heightened risk for individuals with pre-existing CVDs and highlights the role of long-term immune activation and viral antigen persistence.\n    *   **Paper 1 (PMID: 40863226):** This narrative review summarizes current evidence regarding cardiovascular manifestations associated with COVID-19. Acute complications include myocardial injury, arrhythmias (particularly atrial fibrillation), acute coronary syndromes, heart failure, Takotsubo cardiomyopathy, myopericarditis, and cardiac arrest. Right ventricular dysfunction is identified as a key prognostic marker. The review also discusses post-COVID-19 syndrome",
    "finalResponseLength": 2637,
    "finalResponse": "COVID-19 can affect the cardiovascular system in several ways, both during the acute infection phase and in the longer term. Here's a breakdown of the effects, according to the research:\n\n*   **Increased Risk for Those with Pre-existing CVD:** Individuals with pre-existing cardiovascular diseases (CVD) are at a higher risk of experiencing severe COVID-19 and facing increased mortality (PMID: 33162899, 2020; PMID: 38415433, 2024; PMID: 40428732, 2025).\n\n*   **Acute Cardiovascular Complications:** During the active phase of COVID-19, several cardiac complications can arise (PMID: 34046852, 2021; PMID: 37168413, 2023; PMID: 40863226, 2025):\n    *   Myocardial injury and myocarditis (inflammation of the heart muscle)\n    *   Arrhythmias (irregular heartbeats), particularly atrial fibrillation\n    *   Acute coronary syndromes\n    *   Heart failure\n    *   Takotsubo cardiomyopathy (stress-induced heart weakening)\n    *   Myopericarditis (inflammation of the heart muscle and surrounding sac)\n    *   Cardiac arrest\n\n*   **Mechanisms of Cardiovascular Damage:** Several mechanisms contribute to cardiovascular damage (PMID: 33162899, 2020; PMID: 35746609, 2022; PMID: 37168413, 2023; PMID: 40428732, 2025):\n    *   Direct viral entry into heart cells (cardiomyocytes)\n    *   Systemic hyperinflammation and cytokine release syndrome\n    *   Hypercoagulability (increased blood clotting)\n    *   Endothelial injury (damage to the lining of blood vessels)\n    *   Hypoxemia (low blood oxygen)\n    *   RAAS (renin-angiotensin-aldosterone system) dysregulation\n    *   Plaque destabilization\n\n*   **Post-COVID-19 Cardiovascular Issues:** Even after the acute infection resolves, cardiovascular problems can persist (PMID: 40438846, 2025; PMID: 40428732, 2025; PMID: 40863226, 2025):\n    *   Endothelial dysfunction\n    *   Myocardial inflammation\n    *   Autonomic dysregulation\n    *   Persistent arrhythmias\n    *   Subclinical myocardial injury\n\n*   **Prognostic Factors:** Certain factors are associated with poorer outcomes (PMID: 34901278, 2021; PMID: 40438846, 2025):\n    *   Older age (over 60)\n    *   Diabetes mellitus\n    *   Hyperlipidemia\n    *   Hospitalization\n    *   Pre-existing CVD\n    *   Metabolic syndrome\n    *   Right ventricular dysfunction\n\n*   **Pediatric Considerations:** Pediatric inflammatory multisystem syndrome is a major cause of cardiovascular complications in children (PMID: 33162899, 2020).\n\nIt's important to note that while ST-T fragment changes were a common arrhythmia in one study, there was no significant association between specific arrhythmia types and patient outcomes (PMID: 34901278,",
    "retrievedDocs": [
      {
        "title": "Cardiovascular Complications of COVID-19 Disease: A Narrative Review",
        "pmid": "40863226",
        "pubmed_date": "2025 Aug 08",
        "pubmed_abstract": "The coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has had a profound impact on global health, extending beyond pulmonary complications. Cardiovascular involvement in COVID-19 is multifact...",
        "score": 0.831299067
      },
      {
        "title": "COVID-19 and Cardiovascular Complications: A Follow-Up Study from Tertiary Center",
        "pmid": "41157565",
        "pubmed_date": "2025 Sep 24",
        "pubmed_abstract": "(1) Background: In addition to its fatal outcomes, COVID-19 is associated with a spectrum of non-fatal complications that significantly influence clinical trajectories and quality of life. Cardiovascu...",
        "score": 0.810223579
      },
      {
        "title": "Cardiac Complications and COVID-19: A Review of Life-threatening Co-morbidities",
        "pmid": "38415433",
        "pubmed_date": "2024",
        "pubmed_abstract": "The novel 2019 coronavirus disease (COVID-19) was first reported in the last days of December 2019 in Wuhan, China. The presence of certain co-morbidities, including cardiovascular diseases (CVDs), ar...",
        "score": 0.799356818
      },
      {
        "title": "Post-coronavirus Disease 2019 (COVID-19) Cardiovascular Manifestations: A Systematic Review of Long-Term Risks and Outcomes",
        "pmid": "40438846",
        "pubmed_date": "2025 Apr",
        "pubmed_abstract": "Emerging evidence suggests that coronavirus disease 2019 (COVID-19) survivors face increased risks of cardiovascular complications, but the long-term risks, underlying mechanisms, and clinical implica...",
        "score": 0.795289
      },
      {
        "title": "Pathophysiology of Cardiovascular Complications in COVID-19",
        "pmid": "33162899",
        "pubmed_date": "2020",
        "pubmed_abstract": "Numerous recent studies have shown that patients with underlying cardiovascular disease (CVD) are at increased risk of more severe clinical course as well as mortality of COVID-19. Also, the available...",
        "score": 0.790609062
      },
      {
        "title": "Acute Cardiovascular Complications of COVID-19: A Systematic Review",
        "pmid": "37168413",
        "pubmed_date": "2023 May",
        "pubmed_abstract": "Since the pandemic in 2019, coronavirus 2019 (COVID-19) has continued to be linked with a variety of organ systems and complications. While it is generally considered a respiratory disease, its link w...",
        "score": 0.786384404
      },
      {
        "title": "Cardiovascular Tropism and Sequelae of SARS-CoV-2 Infection",
        "pmid": "35746609",
        "pubmed_date": "2022 May 25",
        "pubmed_abstract": "The extrapulmonary manifestation of coronavirus disease-19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), became apparent early in the ongoing pandemic. It is now ...",
        "score": 0.784301579
      },
      {
        "title": "The Involvement and Manifestations of SARS-CoV-2 Virus in Cardiovascular Pathology",
        "pmid": "40428732",
        "pubmed_date": "2025 Apr 22",
        "pubmed_abstract": "Although the acute phase of the COVID-19 pandemic has subsided, the emergence of the post-COVID-19 condition presents a new and complex public health challenge, characterized by persistent, multisyste...",
        "score": 0.781035066
      },
      {
        "title": "Cardiac complications during the active phase of COVID-19: review of the current evidence",
        "pmid": "34046852",
        "pubmed_date": "2021 Nov",
        "pubmed_abstract": "Growing reports since the beginning of the pandemic and till date describe increased rates of cardiac complications (CC) in the active phase of coronavirus disease 2019 (COVID-19). CC commonly observe...",
        "score": 0.780726433
      },
      {
        "title": "Frequency of Cardiovascular Complications and Its Association with Prognosis of COVID-19 Patients",
        "pmid": "34901278",
        "pubmed_date": "2021",
        "pubmed_abstract": "Coronavirus disease 2019 (COVID-19) may lead to acute respiratory disease; cardiovascular, gastrointestinal, and coagulation complications; and even death. One of the major complications is cardiovasc...",
        "score": 0.777369559
      }
    ]
  },
  {
    "testCase": 3,
    "query": "What are the side effects of statins?",
    "description": "Medical query about medication - should summarize findings from multiple papers",
    "success": true,
    "executionTime": 14402,
    "isMedical": true,
    "parsedQuery": "statins adverse effects side effects complications",
    "retrievedDocsCount": 10,
    "researchSummaryLength": 4559,
    "researchSummaryPreview": "Here's a chronological summary of the provided research papers on statins, focusing on key findings and the evolution of understanding:\n\n*   **2012 (PMID: 22936996):** A study of the FDA Adverse Event Reporting System (AERS) database from 2005-2011 found that muscle-related adverse events (AEs) varied among statins. Rosuvastatin had the highest relative risk, followed by atorvastatin and simvastatin, with pravastatin and lovastatin having the lowest. The risk appeared to correlate with LDL-lower",
    "researchSummaryFull": "Here's a chronological summary of the provided research papers on statins, focusing on key findings and the evolution of understanding:\n\n*   **2012 (PMID: 22936996):** A study of the FDA Adverse Event Reporting System (AERS) database from 2005-2011 found that muscle-related adverse events (AEs) varied among statins. Rosuvastatin had the highest relative risk, followed by atorvastatin and simvastatin, with pravastatin and lovastatin having the lowest. The risk appeared to correlate with LDL-lowering potency, with fluvastatin as an exception. The study suggests potency is a predictor of muscle-related AE risk and highlights the importance of considering potency when rechallenging patients who have experienced muscle-related AEs.\n\n*   **2020 (PMID: 33228116):** This review discusses the pleiotropic effects of statins beyond cholesterol lowering. It highlights the role of statin structure and lipophilicity in determining hepatoselectivity and interaction with phospholipid membranes. The paper proposes that non-specific binding due to poor enzyme-ligand sensitivity may contribute to statin intolerance and emphasizes the importance of physicochemical properties in understanding cholesterol-independent effects.\n\n*   **2022 (PMID: 35955495):** This review focuses on neuromuscular adverse effects of statins, which constitute a significant portion of all statin-related adverse events. It covers muscle-related issues (cramps, myalgia, weakness, myopathy, rhabdomyolysis), peripheral neuropathy, and neuromuscular junction dysfunction. The review emphasizes clinical follow-up for early detection and management, including dechallenge or alternative lipid-lowering agents. It anticipates an increase in neuromuscular complications due to the widespread use of statins and suggests pharmacogenomic and environmental studies may help predict these complications.\n\n*   **2022 (PMID: 36558987):** This study analyzed the EudraVigilance database from 2004-2021 for psychiatric adverse drug reactions (ADRs) associated with statins. Atorvastatin, simvastatin, and rosuvastatin were most frequently reported. Insomnia was the most common ADR. Disproportionality analysis suggested a higher reporting probability for psychiatric ADRs (insomnia, nightmares, depression) with statins compared to antiplatelet and antihypertensive drugs, suggesting a potential correlation between statins and psychiatric side effects.\n\n*   **2024 (PMID: 38399268):** This review provides a comprehensive overview of statins, including their mechanism of action, benefits, and risks. It acknowledges statins as the primary treatment for cardiovascular diseases and highlights their pleiotropic effects. However, it also discusses statin-associated symptoms (SAS), such as type 2 diabetes, muscular symptoms, liver toxicity, kidney diseases, cataracts, hemorrhagic strokes, and psychiatric complications, which can lead to dose adjustments or discontinuation.\n\n*   **2024 (PMID: 39840096):** This study analyzed the US FDA Adverse Event Reporting System database from 2004-2024 to investigate statin-related hepatotoxicity. It identified 14,511 cases of hepatic disorders associated with statins, with atorvastatin, simvastatin, and rosuvastatin occurring at higher rates. The study found positive signals for autoimmune hepatitis and drug-induced liver injury across multiple statins. Specific signals were noted for atorvastatin (cholestatic pruritus, bilirubin conjugation abnormal), fluvastatin (autoimmune hepatitis), and simvastatin (weaker signal for hepatic enzyme increased). The results provide insights into potential hepatotoxic risks associated with statin use.\n\n*   **2025 (PMID: 40529509):** This meta-analysis of 41 clinical trials (64,728 individuals) examined the incidence of statin adverse reactions across various diseases. It found that adverse reactions differ across populations. In hyperlipidemia, there was no difference in total adverse events among four statins, but simvastatin 40 mg had fewer statin-related adverse reactions. For coronary heart disease, pravastatin 40 mg resulted in fewer transaminase elevations. Myalgia risk was comparable between different statins in hypercholesterolemia and coronary disease patients, but higher in acute coronary syndrome or stroke patients on high-dose rosuvastatin.\n\n*   **2025 (PMID: 40291284):** This study compared adverse event profiles among seven statins using the FAERS database from 2004-2024, focusing on patients with hypercholesterolemia. It found distinct AE profiles among the statins. With",
    "finalResponseLength": 2057,
    "finalResponse": "Statins can have a range of side effects, as indicated by several research studies. Here's a breakdown:\n\n*   **Muscle-related issues:** These are a common concern. A 2012 study (PMID: 22936996) using the FDA AERS database (2005-2011) found that the risk of muscle-related adverse events varied among different statins. Rosuvastatin, atorvastatin, and simvastatin had higher relative risks, while pravastatin and lovastatin had lower risks. Potency of the statin seemed to correlate with this risk. A 2022 review (PMID: 35955495) also highlighted neuromuscular adverse effects like muscle cramps, myalgia, weakness, myopathy, and rhabdomyolysis as significant issues. A 2025 meta-analysis (PMID: 40529509) found that myalgia risk can vary depending on the patient population and statin dosage.\n\n*   **Psychiatric adverse reactions:** Analysis of the EudraVigilance database (2004-2021) in 2022 (PMID: 36558987) revealed that atorvastatin, simvastatin, and rosuvastatin were most frequently reported for psychiatric adverse drug reactions (ADRs). Insomnia was the most common ADR, and the study suggested a potential link between statins and psychiatric side effects like nightmares and depression.\n\n*   **Liver toxicity:** A 2024 study (PMID: 39840096) analyzing the FDA AERS database (2004-2024) identified 14,511 cases of hepatic disorders associated with statins. Atorvastatin, simvastatin, and rosuvastatin were reported at higher rates. The study found signals for autoimmune hepatitis and drug-induced liver injury.\n\n*   **Other potential side effects:** A 2024 review (PMID: 38399268) mentions statin-associated symptoms (SAS) such as type 2 diabetes, kidney diseases, cataracts, hemorrhagic strokes, and psychiatric complications.\n\n*   **Individual Variation:** A 2025 meta-analysis (PMID: 40529509) of 41 clinical trials found that adverse reactions to statins can differ across various diseases and patient populations.\n\nIt's important to note that the specific adverse event profiles can vary among different statins (PMID: 40291284 - 2025 study).",
    "retrievedDocs": [
      {
        "title": "Hepatotoxicity of statins: a real-world study based on the US Food and Drug Administration Adverse Event Reporting System database",
        "pmid": "39840096",
        "pubmed_date": "2024",
        "pubmed_abstract": "Statins, as an important class of lipid-lowering drugs, play a key role in the prevention and treatment of cardiovascular diseases. However, with their widespread use in clinical practice, some advers...",
        "score": 0.787146449
      },
      {
        "title": "Comparative Analysis of Adverse Event Profiles Among Seven Statins for Hypercholesterolemia Management Using the United States FDA Adverse Event Reporting System",
        "pmid": "40291284",
        "pubmed_date": "2025 Mar",
        "pubmed_abstract": "Background Statins are fundamental in hypercholesterolemia management, with seven primary drugs available: atorvastatin, simvastatin, rosuvastatin, pravastatin, lovastatin, fluvastatin, and pitavastat...",
        "score": 0.781242967
      },
      {
        "title": "Potential Benefits and Risks Associated with the Use of Statins",
        "pmid": "38399268",
        "pubmed_date": "2024 Feb 01",
        "pubmed_abstract": "HMG-CoA reductase inhibitors, commonly known as statins, are the primary treatment choice for cardiovascular diseases, which stand as the leading global cause of mortality. Statins also offer various ...",
        "score": 0.779103
      },
      {
        "title": "A Meta-Analysis of the Incidence of Adverse Reactions of Statins in Various Diseases",
        "pmid": "40529509",
        "pubmed_date": "2025",
        "pubmed_abstract": "Introduction: In clinical practice, patients often avoid or cease statin use due to adverse reactions or noncompliance. To elucidate statin adverse reactions, their variability across diseases, and th...",
        "score": 0.776103616
      },
      {
        "title": "A Survey of the FDA's AERS Database Regarding Muscle and Tendon Adverse Events Linked to the Statin Drug Class",
        "pmid": "22936996",
        "pubmed_date": "2012",
        "pubmed_abstract": "Cholesterol management drugs known as statins are widely used and often well tolerated; however, a variety of muscle-related side effects can arise. These adverse events (AEs) can have serious impact,...",
        "score": 0.763492942
      },
      {
        "title": "Post-Marketing Surveillance of Statins—A Descriptive Analysis of Psychiatric Adverse Reactions in EudraVigilance",
        "pmid": "36558987",
        "pubmed_date": "2022 Dec 10",
        "pubmed_abstract": "Statins are included in the category of high-frequency prescription drugs, and their use is on an upward trend worldwide. In 2012, the FDA issued a warning about possible cognitive adverse drug reacti...",
        "score": 0.761097252
      },
      {
        "title": "Statins Neuromuscular Adverse Effects",
        "pmid": "35955495",
        "pubmed_date": "2022 Jul 28",
        "pubmed_abstract": "Statins are drugs widely prescribed in high-risk patients for cerebrovascular or cardiovascular diseases and are, usually, safe and well tolerated. However, these drugs sometimes may cause neuromuscul...",
        "score": 0.748603
      },
      {
        "title": "Safety Profile of Statins for Post-Marketing Adverse Cardiovascular Events: A Real-World Pharmacovigilance Analysis",
        "pmid": "39473255",
        "pubmed_date": "2025",
        "pubmed_abstract": "The purpose of this study was to comprehensively evaluate the association of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) with neurological adverse events using the U...",
        "score": 0.748583853
      },
      {
        "title": "Hepatotoxicity associated with statins: A retrospective pharmacovigilance study based on the FAERS database",
        "pmid": "40632746",
        "pubmed_date": "2025",
        "pubmed_abstract": "Statins are commonly prescribed in clinical practice and are associated with a high risk of drug-induced liver injury (DILI). This study aims to examine the real-world data on statin-induced liver inj...",
        "score": 0.744264126
      },
      {
        "title": "The Role of Structure and Biophysical Properties in the Pleiotropic Effects of Statins",
        "pmid": "33228116",
        "pubmed_date": "2020 Nov 19",
        "pubmed_abstract": "Statins are a class of drugs used to lower low-density lipoprotein cholesterol and are amongst the most prescribed medications worldwide. Most statins work as a competitive inhibitor of 3-hydroxy-3-me...",
        "score": 0.739772737
      }
    ]
  }
]
```

</details>
